NGVTNYSEChemicals & Allied ProductsFiscal year ends December 31
Ingevity Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$70.31+0.49 (+0.70%)
Close on Oct 19, 2026
- Market cap
- $2.48B
- P/E (TTM)
- 47.8
- Dividend yield
- –
Ingevity Corp revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PM | $160.60M | $155.40M | $151.20M | $155.00M | $153.90M | $146.80M | $156.20M | $151.10M | $157.20M | $145.10M | $152.80M | $147.20M | 51.1% | +4.4% |
| Pavement Technologies | $104.20M | – | – | – | $134.30M | – | – | – | – | – | – | – | 33.2% | -22.4% |
| APT | $49.30M | $44.30M | $36.50M | $38.20M | $43.30M | $42.20M | $43.90M | $48.80M | $47.90M | $48.00M | $42.40M | $42.80M | 15.7% | +13.9% |
| Performance Chemicals | – | $58.30M | $67.40M | $139.90M | $167.90M | $58.90M | $63.20M | $133.90M | $185.50M | $147.00M | $176.50M | $256.00M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PM | $86.10M | $92.00M | $90.20M | $79.90M | $81.00M | $83.50M | $92.40M | $80.60M | $82.20M | $78.00M | $94.60M | $74.50M | +6.3% |
| Pavement Technologies | $25.40M | – | – | – | $28.80M | – | – | – | – | – | – | – | -11.8% |
| APT | $11.20M | $7.60M | $8.80M | $9.90M | $2.00M | $13.60M | $9.90M | $9.80M | $9.80M | $9.50M | $12.40M | $11.20M | +460.0% |
| Performance Chemicals | – | $600.00K | $5.20M | $24.80M | $32.00M | $5.80M | $8.40M | $24.30M | $9.30M | -$10.60M | -$18.80M | $24.70M | – |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $178.00M | $129.20M | $130.70M | $205.10M | $201.10M | $128.20M | $126.80M | $191.80M | $235.60M | $202.70M | $215.20M | $292.40M | 56.7% | -11.5% |
| United States | $156.80M | $112.80M | $115.80M | $181.40M | $178.70M | $112.00M | $105.60M | $168.20M | $345.50M | $183.80M | – | – | 49.9% | -12.3% |
| Asia Pacific | $77.40M | $72.60M | $81.90M | $73.30M | $74.70M | $68.70M | $91.30M | $82.20M | $86.70M | $78.40M | $59.00M | $92.40M | 24.6% | +3.6% |
| Europe, Middle East, and Africa | $47.30M | $44.10M | – | $41.40M | $44.20M | $41.20M | – | $42.90M | $55.30M | $48.30M | – | $48.60M | 15.1% | +7.0% |
| China | $34.10M | $33.10M | $40.60M | $39.60M | $38.30M | $34.70M | $52.40M | $47.20M | $74.20M | $42.20M | – | – | 10.9% | -11.0% |
| South America | $11.40M | $12.10M | $10.40M | $13.30M | $11.50M | $9.80M | $11.70M | $16.90M | $13.00M | $10.70M | $5.40M | $12.60M | 3.6% | -0.9% |
| Europe, Middle East, and Africa | – | – | – | – | – | – | – | – | – | $48.30M | – | – | – | – |
From the segment and revenue-disaggregation notes of Ingevity's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.